NASDAQ · SHC

Sotera Health Company

$17.24 -$0.11 (-0.63%) 1D After hours

Key Metrics

$4.95B
Market cap
42.00×
P/E · TTM
$1.19B
Revenue · TTM
$117.80M
Net income
EPS · TTM $0.42
Dividend yield
Free cash flow $96.84M
Beta · 1Y 1.22
EBITDA · TTM $302.92M
Gross margin 55.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 31
    The stock moved +8.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Mar 27
    From its Feb 2 high, the share price fell 28%.

    Peak close $18.30 on Feb 2; trough close $13.13 on Mar 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.95B
Enterprise value$6.77B
Shares outstanding285.2M
52-wk range$11.00 – $19.85
Avg volume · 20D1.5M
Net cash −$1.82B
Book value / share$2.20
IndustryServices-Misc Health & Allied Services, Nec
ExchangeNASDAQ
About Sotera Health Company
IPO dateNov 20, 2020
Employees3000

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E42.00
P/S4.16
P/FCF51.09
EV/EBITDA22.35
EV/Sales5.69
Graham №$4.53

Profitability

Gross 55.3%
Operating 17.2%
Net 9.9%
FCF 8.1%
ROE / ROIC 22.9% · 4.8%

Financial Health

Current ratio2.82
Quick ratio2.54
Debt / equity3.44
Debt / EBITDA 7.06
Net cash −$1.82B
Working capital$378.17M

Cash Flow · TTM

Operating CF $261.11M
Capex −$164.27M
Free cash flow $96.84M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

1.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$4.53 vs $17.24
Trades 3.8× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings